Wednesday , May 25 2022

Roche arthritis drug shows efficacy for sick patients in Covid-19 trial



[ad_1]

Imperial College London UK has reported that early data from the REMAP-CAP trial shows that Roche’s arthritis drug Actemra (tocilizumab) is expected to reduce deaths and time spent in intensive care in critically ill patients with Covid-19 .

An anti-inflammatory drug, Actemra reached the end of a key efficacy for Covid-19 patients.

The trial is sponsored by UMC Utrecht in Europe and is being led by Imperial College London and ICNARC in the UK.

The analysis included results from 303 patients who received Actemra, sarilumab, anakinra, interferon, or no random immune modulator.

Patients who received Actemra were more likely to recover compared to patients who did not receive any immune modulator, data showed.

Improvement was analyzed based on a combination of the requirements for organ support including ventilator, ICU and survival of hospital admission.

Tocilizumab has been reported to be 99.75% better than immune modulation.

Imperial College London chair of anesthesia and critical care Anthony Gordon said: “These early findings show that a single course of treatment with this immune modulating drug can improve outcomes for the most critically ill Covid-19 patients in care intensive.

“Once we have completed the analysis of the full dataset, we hope that these findings will allow critical care teams around the world to improve the outcomes of sick Covid-19 patients.”

Detailed data from the trial will be published in a couple of weeks.

Separately, the REMAP-CAP trial found the AbbVie AIDS drug cocktail lopinavir / ritonavir cocktail was ineffective and provided no additional benefit to critically ill Covid-19 patients.

In September, Roche had reported that Actemra had reduced the need for ventilators in hospitalized patients with the disease.

The drug also failed in a separate trial of hospitalized patients with Covid-19-related severe pneumonia.



[ad_2]
Source link